Company Overview of Tolerx, Inc.
Tolerx, Inc. develops novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. The company’s products include otelixizumab, a targeted T-cell immunomodulator for treating type 1 diabetes; MTRX1011A, an anti-CD4 antibody for treating autoimmune indications; and TRX518 and TRX385, pre-clinical candidates that focuses on optimizing immune responses for treating cancer and chronic viral diseases. Tolerx, Inc. was formerly known as TolerRx, Inc. and changed its name to Tolerx, Inc. in December 2011. Tolerx, Inc. was founded in 2000 and is based in Cambridge, Massachusetts.
300 Technology Square
Cambridge, MA 02139
Founded in 2000
Key Executives for Tolerx, Inc.
Similar Private Companies By Industry
|The American Cardiovascular Research Institute||United States|
|FGH BioTech, Inc.||United States|
|Ceptaris Therapeutics, Inc.||United States|
|Ascio Pharmaceuticals, Inc.||United States|
|Diatos USA, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Tolerx, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.